The latest announcement is out from Anika Therapeutics ( (ANIK) ).
On March 7, 2025, Anika Therapeutics completed the sale of its subsidiary, Parcus Medical, to Medacta Americas Manufacturing for $4.5 million in cash, marking a strategic move to sharpen its focus on hyaluronic acid-driven osteoarthritis pain management and regenerative solutions. This divestiture is part of Anika’s strategic review to better position itself in its core areas, ensuring a smooth transition for stakeholders and enhancing its market positioning in the orthopedic industry.
More about Anika Therapeutics
Anika Therapeutics, Inc. is a global leader in the Osteoarthritis Pain Management and Regenerative Solutions space, focusing on early intervention orthopedics. The company leverages its expertise in hyaluronic acid and implant solutions to provide minimally invasive products for restoring active living. Anika operates in high-opportunity spaces within orthopedics, including Osteoarthritis Pain Management and Regenerative Solutions, with products delivered in key sites of care such as ambulatory surgery centers. The company’s global operations are headquartered outside of Boston, Massachusetts.
YTD Price Performance: 1.79%
Average Trading Volume: 69,496
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $241.7M
Find detailed analytics on ANIK stock on TipRanks’ Stock Analysis page.